$TEVA Analysts’ Recommendations for Eli Lilly &

$TEVA Analysts’ Recommendations for Eli Lilly & Co. on April 20

Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.



The chart above compares changes in analysts’ recommendations for Eli Lilly & Co. over the last 12 months.

Analysts’ ratings
Eli Lilly’s (LLY) stock price has fallen nearly 1.4% in the last 12 months and nearly 5.6% in 2018 year-to-date. Analysts expect the stock to rise 13.7% over the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $90.70 per share, compared to its price of $79.75 per share on April 19, 2018.

On April 20, 2018, 22 analysts tracked Eli Lilly & Co. Six analysts recommend a “strong buy,” seven analysts recommend a “buy,” eight analysts recommend a “hold,” and one analyst recommends a “sell.” The consensus rating for Eli Lilly & Co. stands at ~2.2, which represents a moderate buy for long-term growth investors and value investors.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.7% of its total investments in Eli Lilly & Co. (LLY), 4.8% in Novo Nordisk ADR (NVO), 4.2% in Teva Pharmaceuticals (TEVA), and 5.3% in AstraZeneca (AZN).